Use of nimesulide in the therapy of rheumatoid diseases


Cite item

Full Text

Abstract

Nimesulide is widely used in 50 countries, including Russia and the EU. A number of clinical trials showed Nimesulide efficacy for correction of disorders associated with lesions of the peripheral joints, spine, periarticular soft tissues in patients with rheumatic diseases. In these studies, nimesulide was effective as other nonsteroidal anti-inflammatory drugs (NSAIDs), and caused a rapid response in patients. In addition, the pharmacokinetics of nimesulide characteristics (short half-life, lack of clinically significant accumulation) and the ability to selective cyclooxygenase-2 inhibition determine the general drug high tolerability. Analysis of the results of its use in general clinical practice shows that nimesulide significantly less likely cause adverse event on the gastrointestinal tract as compared with nonselective NSAIDs.

About the authors

Yu A Olyunin

Yu A Olyunin

References

  1. Насонов Е.Л. Нестероидные противовоспалительные препараты (Перспективы применения в медицине). М., 2000. 143 с.
  2. Насонов Е.Л., Лазебник Л.Б., Беленков Ю.Н. и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М., 2006. 88 с.
  3. Kataoka H, Horie Y, Koyama R, et al. Interaction between NSAIDs and steroid in rat stomach: safety of nimesulide as a preferential COX-2 inhibitor in the stomach. Dig Dis Sci 2000;45(7):1366-75.
  4. Süleyman H, Demircan B, Karagoz Y. Anti-inflammatory and side effects of cyclooxygenase inhibitors. Pharmacol Rep 2007;59(3):247-58.
  5. Traversa G, Bianchi C, Da Cas R, et al. Cohort study of hepatotoxicity associated with nimesulide and other non-steroidal anti-inflammatory drugs. BMJ 2003;327(7405):18-22.
  6. Hudec R, Kriska M, Bozekova L, et al. Comparison of NSAID consumption in Slovakia, Finland and Norway. Bratisl Lek Listy 2008;109(8):370-73.
  7. Motola D, Vaccheri A, Silvani MC, et al. Pattern of NSAID use in the Italian general population: a questionnaire-based survey. Eur J Clin Pharmacol 2004;60(10):731-38.
  8. Suleyman H, Cadirci E, Albayrak A, et al. Nimesulide is a selective COX-2 inhibitory, atypical non-steroidal anti-inflammatory drug. Curr Med Chem 2008;15(3):278-83.
  9. Fabiola GF, Pattabhi V, Nagarajan K. Structural basis for selective inhibition of COX-2 by nimesulide. Bioorg Med Chem 1998;6(12):2337-44.
  10. Bezerra-Netto HJ, Lacerda DI, Miranda AL, et al. Design and synthesis of 3,4-methylenedioxy-6-nitrophenoxyacetylhydrazone derivatives obtained from natural safrole: new lead-agents with analgesic and antipyretic properties. Bioorg Med Chem 2006;14(23):7924-35.
  11. Kerola M, Vuolteenaho K, Kosonen O, et al. Effects of nimesulide, acetylsalicylic acid, ibuprofen and nabumetone on cyclooxygenase-1- and cyclooxygenase-2-mediated prostanoid production in healthy volunteers ex vivo. Basic Clin Pharmacol Toxicol 2009;104(1):17-21.
  12. Tavares IA, Bishai PM, Bennett A. Activity of nimesulide on constitutive and inducible cyclooxygenases. Arzneimittelforschung 1995;45(10):1093-95.
  13. Gambero A, Becker TL, Zago AS, et al. Comparative study of anti-inflammatory and ulcerogenic activities of different cyclo-oxygenase inhibitors. Inflammopharmacology 2005;13(5-6):441-54.
  14. Süleyman H, Demircan B, Goçer F, et al. Role of adrenal gland hormones in the mechanism of antiulcer action of nimesulide and ranitidine. Pol J Pharmacol 2004;56(6):799-804.
  15. Tavares IA, Borrelli F, Welsh NJ. Inhibition of gastric acid secretion by nimesulide: a possible factor in its gastric tolerability. Clin Exp Rheumatol 2001;19(1 Suppl. 22):S13-15.
  16. Crofford LJ, Wilder RL, Ristimaki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest 1994;93(3):1095-101.
  17. Onodera M, Horiuchi Y, Nakahama K, Muneta T, Mano Y, Morita I. Induction of cyclooxygenase-1 in cultured synovial cells isolated from rheumatoid arthritis patients. Inflamm Res. 2004 Jun;53(6):217-22.
  18. Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995;83(3):483-92.
  19. Wallace JL, Chapman K, McKnight W. Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. Br J Pharmacol 1999;126(5):1200-04.
  20. Pelletier JP, Di Battista JA, Zhang M, et al. Effect of nimesulide on glucocorticoid receptor activity in human synovial fibroblasts. Rheumatology (Oxford) 1999;38(Suppl. 1):11-13.
  21. Kimura T, Iwase M, Kondo G, et al. Suppressive effect of selective cyclooxygenase-2 inhibitor on cytokine release in human neutrophils. Int Immunopharmacol 2003;3(10-11):1519-28.
  22. Kullich WC, Niksic F, Klein G. Effect of nimesulide on metalloproteinases and matrix degradation in osteoarthritis: a pilot clinical study. Int J Clin Pract 2002;(128 Suppl.):24-29.
  23. Jovanovic D, Kilibarda V, Todorovic V, et al. A pharmacokinetic comparison of three pharmaceutical formulations of nimesulide in healthy volunteers. Vojnosanit Pregl 2005;62(12):887-93.
  24. Bernareggi A. Clinical pharmacokinetics of nimesulide. Clin Pharmacokinet 1998;35(4):247-74.
  25. Bourgeois P, Dreiser RL, Lequesne MG, et al. Multi-centre double-blind study to define the most favourable dose of nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis. Eur J Rheumatol Inflamm 1994;14(2):39-50.
  26. Kriegel W, Korff KJ, Ehrlich JC, et al. Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int J Clin Pract 2001;55(8):510-14.
  27. Fioravanti A, Storri L, Di Martino S, et al. A randomized, double-blind, multicenter trial of nimesulide-beta-cyclodextrin versus naproxen in patients with osteoarthritis. Clin Ther 2002;24(4):504-19.
  28. Herrera JA, Gonzalez M. Comparative evaluation of the effectiveness and tolerability of nimesulide versus rofecoxib taken once a day in the treatment of patients with knee osteoarthritis. Am J Ther 2003;10(6):468-72.
  29. Bianchi M, Broggini M, Balzarini P, et al. Effects of nimesulide on pain and on synovial fluid concentrations of substance P, interleukin-6 and interleukin-8 in patients with knee osteoarthritis: comparison with celecoxib. Int J Clin Pract 2007;61(8):1270-77.
  30. Pohjolainen T, Jekunen A, Autio L, et al. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine 2000;25(12):1579-85.
  31. Magaro M, Altomonte L, Zoli A, et al. Nimesulide in the treatment of osteoarthrosis and extra-articular rheumatism. Minerva Med 1989;80(9):1015-18.
  32. Wober W. Comparative efficacy and safety of nimesulide and diclofenac in patients with acute shoulder, and a meta-analysis of controlled studies with nimesulide. Rheumatology (Oxford) 1999;38(Suppl. 1):33-38.
  33. Кудаева Ф.М., Барскова В.Г., Насонова В.А. Сравнение скорости наступления противовоспалительного и анальгетического эффекта таблетированных нимесулидов и диклофенака натрия при подагрическом артрите: рандомизированное исследование // Научно-практическая ревматология. 2008. № 1. С. 55-59.
  34. Bianchi M, Broggini M. Anti-hyperalgesic effects of nimesulide: studies in rats and humans. Int J Clin Pract 2002;(128 Suppl.):11-19.
  35. Балабанова Р.М., Белов Б.С., Чичасова Н.В. и др. Эффективность нимесила при ревматоидном артрите // Клиническая медицина. 2002. № 6. С. 49-52.
  36. Conforti A, Leone R, Moretti U, et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf 2001;24(14):1081-90.
  37. Laporte JR, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004;27(6):411-20.
  38. Senna GE, Passalacqua G, Dama A, et al. Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti-inflammatory drugs. Eur Ann Allergy Clin Immunol 2003;35(10):393-96.
  39. Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 2007;8:73.
  40. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2398&mid=1085056570&magid=179

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies